Cite
Nakamura N, Yoshida K, Tsuda R, et al. Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients. Front Biosci (Landmark Ed). 2021;26(12):1480-1492doi: 10.52586/5042.
Nakamura, N., Yoshida, K., Tsuda, R., Murata, M., Yamaguchi, T., Suwa, K., Ichimura, M., Tsuneyama, K., Matsuzaki, K., Nakano, T., Hirohara, J., Seki, T., Okazaki, K., Gershwin, M. E., & Naganuma, M. (2021). Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients. Frontiers in bioscience (Landmark edition), 26(12), 1480-1492. https://doi.org/10.52586/5042
Nakamura, Naohiro, et al. "Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients." Frontiers in bioscience (Landmark edition) vol. 26,12 (2021): 1480-1492. doi: https://doi.org/10.52586/5042
Nakamura N, Yoshida K, Tsuda R, Murata M, Yamaguchi T, Suwa K, Ichimura M, Tsuneyama K, Matsuzaki K, Nakano T, Hirohara J, Seki T, Okazaki K, Gershwin ME, Naganuma M. Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients. Front Biosci (Landmark Ed). 2021 Dec 30;26(12):1480-1492. doi: 10.52586/5042. PMID: 34994163.
Copy
Download .nbib